Understanding how glioblastoma interacts with neurons and immune cells
Official title: Quantitative systems biology of glioblastoma cells and their interactions with the neuronal and immunological milieu
Funded at Massachusetts Institute of Technology · NIH-10930062 · Data updated 2026-11-12
This study is looking at how glioblastoma cells interact with brain cells and immune cells to see how these relationships affect tumor growth and treatment, with the goal of finding new ways to help patients with this type of brain cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,901,909 |
| NIH project number | 5U54CA283114-02 |
| Project ID | NIH-10930062 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research investigates the complex interactions between glioblastoma cells, neurons, and immune cells to better understand how these relationships affect tumor growth and response to treatment. By developing a systems-level model, the research aims to analyze how tumor cells influence neural signaling and how immune cells interact with the tumor microenvironment. The approach includes using various biological models and computational methods to simulate these interactions, ultimately aiming to identify new therapeutic strategies that could improve treatment outcomes for patients with glioblastoma.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in understanding tumor-immune interactions, suggesting that this approach could yield valuable insights and advancements in glioblastoma treatment.
Where this research is happening
-
Massachusetts Institute of Technology
Cambridge, United States Active
Researchers
- Principal investigator: White, Forest M — Massachusetts Institute of Technology
- Study coordinator: White, Forest M
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.